218 related articles for article (PubMed ID: 21912253)
1. Have we improved in preventing and treating acute graft-versus-host disease?
Perez L; Anasetti C; Pidala J
Curr Opin Hematol; 2011 Nov; 18(6):408-13. PubMed ID: 21912253
[TBL] [Abstract][Full Text] [Related]
2. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding.
Nunes NS; Kanakry CG
Front Immunol; 2019; 10():2668. PubMed ID: 31849930
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
5. Thinking out of the box--new approaches to controlling GVHD.
Baron F; Humblet-Baron S; Ehx G; Servais S; Hannon M; Belle L; Lechanteur C; Briquet A; Giet O; Baudoux E; Willems E; Beguin Y
Curr Hematol Malig Rep; 2014 Mar; 9(1):73-84. PubMed ID: 24390548
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Advances in the understanding of acute graft-versus-host disease.
Morris ES; Hill GR
Br J Haematol; 2007 Apr; 137(1):3-19. PubMed ID: 17359368
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T Cells in GVHD Therapy.
Guo WW; Su XH; Wang MY; Han MZ; Feng XM; Jiang EL
Front Immunol; 2021; 12():697854. PubMed ID: 34220860
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease.
Li M; Sun K; Welniak LA; Murphy WJ
Expert Opin Pharmacother; 2008 Sep; 9(13):2305-16. PubMed ID: 18710355
[TBL] [Abstract][Full Text] [Related]
11. Progress and prospects: graft-versus-host disease.
Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
[TBL] [Abstract][Full Text] [Related]
12. Novel drugs for the prevention and treatment of acute GVHD.
Cutler C; Antin JH
Curr Pharm Des; 2008; 14(20):1962-73. PubMed ID: 18691107
[TBL] [Abstract][Full Text] [Related]
13. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
14. Management of acute graft versus host disease (GvHD).
Bacigalupo A; Palandri F
Hematol J; 2004; 5(3):189-96. PubMed ID: 15167903
[TBL] [Abstract][Full Text] [Related]
15. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies.
Zeiser R; Marks R; Bertz H; Finke J
Ann Hematol; 2004 Sep; 83(9):551-65. PubMed ID: 15449032
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
17. Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?
Pidala J; Anasetti C
Haematologica; 2010 Apr; 95(4):660-5. PubMed ID: 20015881
[TBL] [Abstract][Full Text] [Related]
18. The role of regulatory T cells in graft-versus-host disease management.
Whangbo JS; Antin JH; Koreth J
Expert Rev Hematol; 2020 Feb; 13(2):141-154. PubMed ID: 31874061
[No Abstract] [Full Text] [Related]
19. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
[TBL] [Abstract][Full Text] [Related]
20. New approaches for preventing and treating chronic graft-versus-host disease.
Lee SJ
Blood; 2005 Jun; 105(11):4200-6. PubMed ID: 15701727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]